Next Generation Sequencing. a Key in Search of Locks?

Multi-platform Tumour Profiling Delivers the Highest Clinical Utility and Improves Patient Outcomes in Today's Routine Clinical Practice

“…The majority of individual mutations are relatively rare, and the access to targeted therapies effective against these alterations outside clinical trials is difficult and often outside the financial reach of patients. As a result, the utility of 'Next Generation' sequencing alone is limited in routine clinical practice, with fewer than 20% of profiled patients receiving a treatment based on the results of sequencing [16][17][18][19]]. Examining the proteins and RNA as well as the genetic sequence in a multiplatform approach greatly increases the number of possible targets and therefore possible treatment options.…”